Timbetasin

Unassigned

New Medicines

Dry eye syndrome

Information

New molecular entity
RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Synthetic version of an endogenous 43-amino acid hormone that reduces inflammation and has been shown to repair corneal damage in the animal dry eye model
Dry eye syndrome, is a common condition caused by a disorder of the tear film. Reported prevalence rates are 15-33% in people aged 65 and over. It is around 50% more common in women than in men, & can have significant effects on quality of life & common vision-related daily activities, such as driving & reading [1].
Dry eye syndrome
Topical

Evidence based evaluations

Neurotrophic keratopathy stage 3 or 4

Information

New molecular entity
RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals

Development and Regulatory status

None
None
Suspended
Yes

Category

Synthetic version of an endogenous 43-amino acid hormone that reduces inflammation and has been shown to repair corneal damage in the animal dry eye model
Neurotrophic keratopathy is a serious degenerative disease of the corneal epithelium, designated an orphan disease in the US and EU. Estimated US and EU prevalence of all stages of neurotrophic keratopathy is less than 50,000 in each region and less than 10,000 with Stage 2 or 3 [2,5].
Neurotrophic keratopathy stage 3 or 4
Topical

Evidence based evaluations